Relationship between the Binding Sites for von Willebrand Factor, Phospholipid, and Human Factor VIII C2 Inhibitor Alloantibodies within the Factor ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2007-05-01

AUTHORS

Keiji Nogami, Midori Shima, John C. Giddings, Masahiro Takeyama, Ichiro Tanaka, Akira Yoshioka

ABSTRACT

Some factor VIII (FVIII) inhibitor alloantibodies block FVIII binding to von Willebrand factor (VWF) and phospholipid (PL) and recognize a C2 domain epitope that overlaps both binding sites. We previously showed that FVIII peptide 2315-2330 neutralized FVIII inhibitors and that Cys2326 and Glu2327 contributed to the maximum neutralizing effect. In the present study, we investigated the relationship between the essential binding sites for VWF, PL, and anti-C2 inhibitors by means of competitive-inhibition assays with overlapping synthetic peptides that span the C terminus of the C2 domain (residues 2288-2332). We identified 2 peptides (residues 2303–2317 and 2315–2330) that specifically blocked FVIII binding to VWF or PL by approximately 80% (50%-inhibitory concentration [IC50], 9.0 μM) and 95% (IC50, 0.12 ?M), respectively. To examine in detail the residues responsible for PL binding, we prepared mutants of peptide 2315-2330 in which we sequentially substituted each residue with Gly. Two residues, Ile2317 and Met2321, were shown to be essential for PL binding. Their substitution with Gly reduced the inhibitory effect by >90%.The data suggest that the binding sites for VWF, PL, and anti-C2 inhibitors in the C2 domain are in very close proximity but are not identical. More... »

PAGES

317-322

Identifiers

URI

http://scigraph.springernature.com/pub.10.1532/ijh97.06192

DOI

http://dx.doi.org/10.1532/ijh97.06192

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1014493590

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17483075


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1101", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Biochemistry and Metabolomics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Amino Acid Substitution", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Binding Sites", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Coagulation Factor Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Epitope Mapping", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Factor VIII", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Isoantibodies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mutation, Missense", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phospholipids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Structure, Tertiary", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "von Willebrand Factor", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Pediatrics, Nara Medical University, 840 Shijo-cho, 634-8522, Kashihara City, Nara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410814.8", 
          "name": [
            "Department of Pediatrics, Nara Medical University, 840 Shijo-cho, 634-8522, Kashihara City, Nara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nogami", 
        "givenName": "Keiji", 
        "id": "sg:person.0603447532.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603447532.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pediatrics, Nara Medical University, 840 Shijo-cho, 634-8522, Kashihara City, Nara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410814.8", 
          "name": [
            "Department of Pediatrics, Nara Medical University, 840 Shijo-cho, 634-8522, Kashihara City, Nara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shima", 
        "givenName": "Midori", 
        "id": "sg:person.0705772523.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0705772523.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Wales College of Medicine, Cardiff University, UK", 
          "id": "http://www.grid.ac/institutes/grid.5600.3", 
          "name": [
            "Department of Haematology, Wales College of Medicine, Cardiff University, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Giddings", 
        "givenName": "John C.", 
        "id": "sg:person.0107141010.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0107141010.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pediatrics, Nara Medical University, 840 Shijo-cho, 634-8522, Kashihara City, Nara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410814.8", 
          "name": [
            "Department of Pediatrics, Nara Medical University, 840 Shijo-cho, 634-8522, Kashihara City, Nara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takeyama", 
        "givenName": "Masahiro", 
        "id": "sg:person.0766011332.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0766011332.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pediatrics, Nara Medical University, 840 Shijo-cho, 634-8522, Kashihara City, Nara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410814.8", 
          "name": [
            "Department of Pediatrics, Nara Medical University, 840 Shijo-cho, 634-8522, Kashihara City, Nara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tanaka", 
        "givenName": "Ichiro", 
        "id": "sg:person.0637242452.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637242452.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pediatrics, Nara Medical University, 840 Shijo-cho, 634-8522, Kashihara City, Nara, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410814.8", 
          "name": [
            "Department of Pediatrics, Nara Medical University, 840 Shijo-cho, 634-8522, Kashihara City, Nara, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yoshioka", 
        "givenName": "Akira", 
        "id": "sg:person.01102237732.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102237732.38"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/312337a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044256805", 
          "https://doi.org/10.1038/312337a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/46601", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033020400", 
          "https://doi.org/10.1038/46601"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/312330a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007542850", 
          "https://doi.org/10.1038/312330a0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-05-01", 
    "datePublishedReg": "2007-05-01", 
    "description": "Some factor VIII (FVIII) inhibitor alloantibodies block FVIII binding to von Willebrand factor (VWF) and phospholipid (PL) and recognize a C2 domain epitope that overlaps both binding sites. We previously showed that FVIII peptide 2315-2330 neutralized FVIII inhibitors and that Cys2326 and Glu2327 contributed to the maximum neutralizing effect. In the present study, we investigated the relationship between the essential binding sites for VWF, PL, and anti-C2 inhibitors by means of competitive-inhibition assays with overlapping synthetic peptides that span the C terminus of the C2 domain (residues 2288-2332). We identified 2 peptides (residues 2303\u20132317 and 2315\u20132330) that specifically blocked FVIII binding to VWF or PL by approximately 80% (50%-inhibitory concentration [IC50], 9.0 \u03bcM) and 95% (IC50, 0.12 ?M), respectively. To examine in detail the residues responsible for PL binding, we prepared mutants of peptide 2315-2330 in which we sequentially substituted each residue with Gly. Two residues, Ile2317 and Met2321, were shown to be essential for PL binding. Their substitution with Gly reduced the inhibitory effect by >90%.The data suggest that the binding sites for VWF, PL, and anti-C2 inhibitors in the C2 domain are in very close proximity but are not identical.", 
    "genre": "article", 
    "id": "sg:pub.10.1532/ijh97.06192", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1076985", 
        "issn": [
          "0925-5710", 
          "1865-3774"
        ], 
        "name": "International Journal of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "85"
      }
    ], 
    "keywords": [
      "von Willebrand factor", 
      "Willebrand factor", 
      "PL binding", 
      "C2 domain epitopes", 
      "FVIII inhibitors", 
      "competitive inhibition assays", 
      "domain epitopes", 
      "inhibitory effect", 
      "FVIII", 
      "alloantibodies", 
      "factor VIII C2 domain", 
      "inhibitors", 
      "present study", 
      "binding sites", 
      "synthetic peptides", 
      "peptides", 
      "epitopes", 
      "factors", 
      "C2 domain", 
      "binding", 
      "assays", 
      "effect", 
      "sites", 
      "essential binding sites", 
      "phospholipids", 
      "Gly", 
      "C-terminus", 
      "close proximity", 
      "relationship", 
      "study", 
      "data", 
      "PL", 
      "domain", 
      "residues", 
      "mutants", 
      "means", 
      "terminus", 
      "substitution", 
      "proximity", 
      "detail"
    ], 
    "name": "Relationship between the Binding Sites for von Willebrand Factor, Phospholipid, and Human Factor VIII C2 Inhibitor Alloantibodies within the Factor VIII C2 Domain", 
    "pagination": "317-322", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1014493590"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1532/ijh97.06192"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17483075"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1532/ijh97.06192", 
      "https://app.dimensions.ai/details/publication/pub.1014493590"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T20:52", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_429.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1532/ijh97.06192"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1532/ijh97.06192'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1532/ijh97.06192'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1532/ijh97.06192'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1532/ijh97.06192'


 

This table displays all metadata directly associated to this object as RDF triples.

195 TRIPLES      21 PREDICATES      79 URIs      68 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1532/ijh97.06192 schema:about N04bd0714e201470397a0b0d9e1682c5a
2 N09a759cf4b51442dba46a6ead90ad422
3 N1228c9c1c8fd46cda9fadcd07a8415e2
4 N22010a87c40a44f6b8941e8116a96f9d
5 N6379c6ff63fd41f0aaf4754012ed1bab
6 N80c9a7aa4aa7429eb336e61cc7df49af
7 Nb20a59e91de243c2ab0b5fdb5775ff85
8 Nbe9cf07a2d654e6c83328a4e9ca2aefb
9 Nc59ec986204640909cc6a57be8dd3b81
10 Nd378d087443649aab127997a912fb5e2
11 Nff125ac048444345b253d54ea08c0a3e
12 anzsrc-for:11
13 anzsrc-for:1101
14 schema:author N952f502bd9604d7ab98178945d5ad632
15 schema:citation sg:pub.10.1038/312330a0
16 sg:pub.10.1038/312337a0
17 sg:pub.10.1038/46601
18 schema:datePublished 2007-05-01
19 schema:datePublishedReg 2007-05-01
20 schema:description Some factor VIII (FVIII) inhibitor alloantibodies block FVIII binding to von Willebrand factor (VWF) and phospholipid (PL) and recognize a C2 domain epitope that overlaps both binding sites. We previously showed that FVIII peptide 2315-2330 neutralized FVIII inhibitors and that Cys2326 and Glu2327 contributed to the maximum neutralizing effect. In the present study, we investigated the relationship between the essential binding sites for VWF, PL, and anti-C2 inhibitors by means of competitive-inhibition assays with overlapping synthetic peptides that span the C terminus of the C2 domain (residues 2288-2332). We identified 2 peptides (residues 2303–2317 and 2315–2330) that specifically blocked FVIII binding to VWF or PL by approximately 80% (50%-inhibitory concentration [IC50], 9.0 μM) and 95% (IC50, 0.12 ?M), respectively. To examine in detail the residues responsible for PL binding, we prepared mutants of peptide 2315-2330 in which we sequentially substituted each residue with Gly. Two residues, Ile2317 and Met2321, were shown to be essential for PL binding. Their substitution with Gly reduced the inhibitory effect by >90%.The data suggest that the binding sites for VWF, PL, and anti-C2 inhibitors in the C2 domain are in very close proximity but are not identical.
21 schema:genre article
22 schema:isAccessibleForFree false
23 schema:isPartOf N0ede3b109fce43a1bb38d73fc57501a1
24 N96fe4028eb844361a37fbdb05c4ba56e
25 sg:journal.1076985
26 schema:keywords C-terminus
27 C2 domain
28 C2 domain epitopes
29 FVIII
30 FVIII inhibitors
31 Gly
32 PL
33 PL binding
34 Willebrand factor
35 alloantibodies
36 assays
37 binding
38 binding sites
39 close proximity
40 competitive inhibition assays
41 data
42 detail
43 domain
44 domain epitopes
45 effect
46 epitopes
47 essential binding sites
48 factor VIII C2 domain
49 factors
50 inhibitors
51 inhibitory effect
52 means
53 mutants
54 peptides
55 phospholipids
56 present study
57 proximity
58 relationship
59 residues
60 sites
61 study
62 substitution
63 synthetic peptides
64 terminus
65 von Willebrand factor
66 schema:name Relationship between the Binding Sites for von Willebrand Factor, Phospholipid, and Human Factor VIII C2 Inhibitor Alloantibodies within the Factor VIII C2 Domain
67 schema:pagination 317-322
68 schema:productId N1cc55fc5162e4bdebb12ad89cc800f89
69 N6cc5c7eb2a3348cb9d0b912122557a8a
70 N7a6a2d09a1ac419094a6d7d76ba4c5dc
71 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014493590
72 https://doi.org/10.1532/ijh97.06192
73 schema:sdDatePublished 2022-11-24T20:52
74 schema:sdLicense https://scigraph.springernature.com/explorer/license/
75 schema:sdPublisher N80f912bbdc67463ea2ef829385b52f40
76 schema:url https://doi.org/10.1532/ijh97.06192
77 sgo:license sg:explorer/license/
78 sgo:sdDataset articles
79 rdf:type schema:ScholarlyArticle
80 N04bd0714e201470397a0b0d9e1682c5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Protein Structure, Tertiary
82 rdf:type schema:DefinedTerm
83 N09a759cf4b51442dba46a6ead90ad422 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Humans
85 rdf:type schema:DefinedTerm
86 N0ede3b109fce43a1bb38d73fc57501a1 schema:volumeNumber 85
87 rdf:type schema:PublicationVolume
88 N105819c7544741729b5c0675315f8086 rdf:first sg:person.0766011332.86
89 rdf:rest N944f475a812c4d05a723bb73c1e3b2eb
90 N1228c9c1c8fd46cda9fadcd07a8415e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Isoantibodies
92 rdf:type schema:DefinedTerm
93 N1cc55fc5162e4bdebb12ad89cc800f89 schema:name dimensions_id
94 schema:value pub.1014493590
95 rdf:type schema:PropertyValue
96 N1e20777a11d74f2da8ea6ea4a0f2626d rdf:first sg:person.0107141010.85
97 rdf:rest N105819c7544741729b5c0675315f8086
98 N22010a87c40a44f6b8941e8116a96f9d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Mutation, Missense
100 rdf:type schema:DefinedTerm
101 N229241a583b8418db892d63fe416b4b1 rdf:first sg:person.01102237732.38
102 rdf:rest rdf:nil
103 N6379c6ff63fd41f0aaf4754012ed1bab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Amino Acid Substitution
105 rdf:type schema:DefinedTerm
106 N6abd65c0b7af4ff3b9af638d1d89e5a7 rdf:first sg:person.0705772523.06
107 rdf:rest N1e20777a11d74f2da8ea6ea4a0f2626d
108 N6cc5c7eb2a3348cb9d0b912122557a8a schema:name pubmed_id
109 schema:value 17483075
110 rdf:type schema:PropertyValue
111 N7a6a2d09a1ac419094a6d7d76ba4c5dc schema:name doi
112 schema:value 10.1532/ijh97.06192
113 rdf:type schema:PropertyValue
114 N80c9a7aa4aa7429eb336e61cc7df49af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Epitope Mapping
116 rdf:type schema:DefinedTerm
117 N80f912bbdc67463ea2ef829385b52f40 schema:name Springer Nature - SN SciGraph project
118 rdf:type schema:Organization
119 N944f475a812c4d05a723bb73c1e3b2eb rdf:first sg:person.0637242452.78
120 rdf:rest N229241a583b8418db892d63fe416b4b1
121 N952f502bd9604d7ab98178945d5ad632 rdf:first sg:person.0603447532.27
122 rdf:rest N6abd65c0b7af4ff3b9af638d1d89e5a7
123 N96fe4028eb844361a37fbdb05c4ba56e schema:issueNumber 4
124 rdf:type schema:PublicationIssue
125 Nb20a59e91de243c2ab0b5fdb5775ff85 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Factor VIII
127 rdf:type schema:DefinedTerm
128 Nbe9cf07a2d654e6c83328a4e9ca2aefb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name von Willebrand Factor
130 rdf:type schema:DefinedTerm
131 Nc59ec986204640909cc6a57be8dd3b81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Phospholipids
133 rdf:type schema:DefinedTerm
134 Nd378d087443649aab127997a912fb5e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Blood Coagulation Factor Inhibitors
136 rdf:type schema:DefinedTerm
137 Nff125ac048444345b253d54ea08c0a3e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Binding Sites
139 rdf:type schema:DefinedTerm
140 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
141 schema:name Medical and Health Sciences
142 rdf:type schema:DefinedTerm
143 anzsrc-for:1101 schema:inDefinedTermSet anzsrc-for:
144 schema:name Medical Biochemistry and Metabolomics
145 rdf:type schema:DefinedTerm
146 sg:journal.1076985 schema:issn 0925-5710
147 1865-3774
148 schema:name International Journal of Hematology
149 schema:publisher Springer Nature
150 rdf:type schema:Periodical
151 sg:person.0107141010.85 schema:affiliation grid-institutes:grid.5600.3
152 schema:familyName Giddings
153 schema:givenName John C.
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0107141010.85
155 rdf:type schema:Person
156 sg:person.01102237732.38 schema:affiliation grid-institutes:grid.410814.8
157 schema:familyName Yoshioka
158 schema:givenName Akira
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01102237732.38
160 rdf:type schema:Person
161 sg:person.0603447532.27 schema:affiliation grid-institutes:grid.410814.8
162 schema:familyName Nogami
163 schema:givenName Keiji
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603447532.27
165 rdf:type schema:Person
166 sg:person.0637242452.78 schema:affiliation grid-institutes:grid.410814.8
167 schema:familyName Tanaka
168 schema:givenName Ichiro
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637242452.78
170 rdf:type schema:Person
171 sg:person.0705772523.06 schema:affiliation grid-institutes:grid.410814.8
172 schema:familyName Shima
173 schema:givenName Midori
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0705772523.06
175 rdf:type schema:Person
176 sg:person.0766011332.86 schema:affiliation grid-institutes:grid.410814.8
177 schema:familyName Takeyama
178 schema:givenName Masahiro
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0766011332.86
180 rdf:type schema:Person
181 sg:pub.10.1038/312330a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007542850
182 https://doi.org/10.1038/312330a0
183 rdf:type schema:CreativeWork
184 sg:pub.10.1038/312337a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044256805
185 https://doi.org/10.1038/312337a0
186 rdf:type schema:CreativeWork
187 sg:pub.10.1038/46601 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033020400
188 https://doi.org/10.1038/46601
189 rdf:type schema:CreativeWork
190 grid-institutes:grid.410814.8 schema:alternateName Department of Pediatrics, Nara Medical University, 840 Shijo-cho, 634-8522, Kashihara City, Nara, Japan
191 schema:name Department of Pediatrics, Nara Medical University, 840 Shijo-cho, 634-8522, Kashihara City, Nara, Japan
192 rdf:type schema:Organization
193 grid-institutes:grid.5600.3 schema:alternateName Department of Haematology, Wales College of Medicine, Cardiff University, UK
194 schema:name Department of Haematology, Wales College of Medicine, Cardiff University, UK
195 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...